Comparison between Targeted Radionuclide Therapy of Bone Metastases Based on β-Emitting and α-Emitting Radionuclides

Sadremomtaz, Alireza; Masoumi, Mahboubeh

doi:10.1016/j.jmir.2018.12.005

Cited by 5 publications

(1 citation statement)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To recapitulate, [ 177 Lu]lutetium may be more available considering the established use in radionuclide therapy for neuroendocrine tumors and prostate cancers. Also, the features of relatively inexpensive [ 177 Lu]lutetium, such as favorable half-life, production in high-specific activity, efficient therapeutic β¯-particles, longer effect with a single administration, lower radiation of bone marrow and sufficient γ-photons for imaging make it an interesting radioisotope in bone-pain palliation therapy [ 32 , 33 , 34 , 109 , 110 ]. The impact of [ 177 Lu]Lu-phosphonate complexes in increasing survival indices is not addressed, fairly.…”

Section: [177 Lu]lutetium-ethylene Diamine Tetramethylene Phosphomentioning

confidence: 99%

Targeted Palliative Radionuclide Therapy for Metastatic Bone Pain

Manafi‐Farid

Masoumi

Divband

et al. 2020

JCM

View full text Add to dashboard Cite

Bone metastasis develops in multiple malignancies with a wide range of incidence. The presence of multiple bone metastases, leading to a multitude of complications and poorer prognosis. The corresponding refractory bone pain is still a challenging issue managed through multidisciplinary approaches to enhance the quality of life. Radiopharmaceuticals are mainly used in the latest courses of the disease. Bone-pain palliation with easy-to-administer radionuclides offers advantages, including simultaneous treatment of multiple metastatic foci, the repeatability and also the combination with other therapies. Several β¯- and α-emitters as well as pharmaceuticals, from the very first [89Sr]strontium-dichloride to recently introduced [223Ra]radium-dichloride, are investigated to identify an optimum agent. In addition, the combination of bone-seeking radiopharmaceuticals with chemotherapy or radiotherapy has been employed to enhance the outcome. Radiopharmaceuticals demonstrate an acceptable response rate in pain relief. Nevertheless, survival benefits have been documented in only a limited number of studies. In this review, we provide an overview of bone-seeking radiopharmaceuticals used for bone-pain palliation, their effectiveness and toxicity, as well as the results of the combination with other therapies. Bone-pain palliation with radiopharmaceuticals has been employed for eight decades. However, there are still new aspects yet to be established.

show abstract